CSPC PHARMA (01093) has announced that the Phase Ib/II clinical trial of its developed SYH2051 combined with irinotecan liposome for the treatment of advanced solid tumors has officially been initiated at the first research site in China.
The product is a highly selective inhibitor of ataxia-telangiectasia mutated (ATM) protein kinase, registered as a Class 1 chemical drug. It selectively inhibits the activity of ATM kinase, a core component of the cellular DNA damage repair system, thereby preventing DNA damage repair in tumor cells.
The clinical trial now launched is a multicenter, open-label Phase Ib/II study designed to enroll patients with advanced solid tumors, aiming to evaluate the safety and efficacy of the product in combination with irinotecan liposome.
Currently, participant recruitment and screening for this clinical trial are being actively advanced.